pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
235
stories
8d
STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
stat
10d
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
biopharma dive
10d
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
endpoints
10d
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
stat
10d
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
fiercebiotech
11d
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
11d
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
12d
Novartis' drug delivery deal with Alteogen; More worker cuts at Cellares
endpoints
12d
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
endpoints
12d
STAT+: Fauci speaks, and writes
stat
12d
STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
stat
12d
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
12d
Opinion: STAT+: A surprising bright spot at the FDA on regulating unproven stem cells
stat
12d
STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
stat
12d
Novartis CAR-T deaths raise questions over acceptable autoimmune risk
endpoints
13d
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
13d
Novartis telegraphs 130 job cuts amid biologics rethink in Switzerland
fiercebiotech
13d
STAT+: ARPA-H funds biotechs working on custom RNA therapies
stat
13d
STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
stat
13d
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
biospace
13d
Teva autoimmune antibody notches ph. 2 win in celiac disease
fiercebiotech
13d
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
biospace
13d
Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen
fiercebiotech
14d
Novartis says MS pill succeeds in two large studies
biopharma dive
14d
STAT+: 5 burning questions on Trump’s latest deals with drugmakers
stat
14d
STAT+: Novartis gets multiple sclerosis win with BTK inhibitor
stat
14d
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
14d
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
14d
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
14d
Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
endpoints
← prev
page 3 of 8
next →
